Evidence map›Paper›PMID 34342740›Full record

ArticleClinical rheumatology2021

Indications and diagnostic outcome of antineutrophil cytoplasmic antibody testing in hospital medicine: a pattern of over-screening.

Yanzhu Xu, Noren Khamis, Touraj Khosravi-Hafshejani, Julia Tan, Ellen Miles, J Antonio Avina-Zubieta, Kam Shojania, Michael Nimmo, Natasha Dehghan

Abstract read
PubMed Publisher
In one paragraph

Article in Clinical rheumatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Yanzhu XuDepartment of Medicine, University of British Columbia, Vancouver, BC, Canada.ORCID http://orcid.org/0000-0001-6449-4255
Noren KhamisFaculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
Touraj Khosravi-HafshejaniFaculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
Julia TanFaculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
Ellen MilesDepartment of Medicine, University of British Columbia, Vancouver, BC, Canada.
J Antonio Avina-ZubietaFaculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
Kam ShojaniaFaculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
Michael NimmoFaculty of Medicine, University of British Columbia, Vancouver, BC, Canada.
Natasha DehghanFaculty of Medicine, University of British Columbia, Vancouver, BC, Canada. polarisrheumatology@gmail.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

INTRODUCTION/

objectiveAntineutrophil cytoplasmic antibodies (ANCA) serology can aid in the diagnosis and classification of ANCA-associated vasculitides (AAV). However, it is often ordered in patients without clinical manifestations of vasculitis. In this retrospective chart review, we aim to better understand the clinical practices on ANCA testing.

methodsWe retrospectively reviewed patients' charts for the indications and diagnostic outcomes of ANCA tests. All ANCA tests ordered at two Canadian hospitals (a community hospital and an academic tertiary hospital) between January and December 2016 were included in the study. Descriptive statistics are used.

resultsA total of 302 ANCA tests were included. The majority (n = 198, 65.6%) were ordered without an indication for testing. For those patients with at least 1 clinical manifestation of AAV (n = 104), 25% were ANCA positive and 18.3% resulted in a diagnosis of AAV. In comparison, among those without a clinical manifestation of AAV (n = 198), only 1.5% were ANCA positive and none was diagnosed with AAV. All patients diagnosed with AAV had at least 1 indication for ANCA testing. The three most common clinical presentations in patients with a final diagnosis of AAV were glomerulonephritis (81.8%), pulmonary hemorrhage (45.5%), and multiple lung nodules (31.8%).

conclusionTo our knowledge, this is the first study that evaluates patients with both positive and negative ANCA test results in an inpatient setting. We demonstrated a low rate of ANCA positivity and AAV diagnosis in patients without clinical manifestations of AAV. Overall, there is a high rate of ANCA testing without an indication at our academic institution. This over-testing may be curbed by strategies such as a gating policy, culture changes, and clinician education. Key Points • AAV is a clinical-pathological diagnosis, and despite the usefulness of ANCA testing, it does not confirm nor rule out AAV. • ANCA testing for the diagnosis of AAV is generally only indicated when there is a clear manifestation of AAV. • Although patients with AAV may occasionally present without classic signs and symptoms, the diagnostic utility of ANCA serology in this setting is low, and testing is more likely to result in a false-positive or false-negative test. • If clinical suspicion remains high despite negative ANCA testing, clinicians should seek consultation with a rheumatologist.

Indexed as

Anti-Neutrophil Cytoplasmic Antibody-Associated VasculitisHospital MedicineAntibodies, Antineutrophil CytoplasmicCanadaHumansPeroxidaseRetrospective StudiesAntibodies, Antineutrophil CytoplasmicPeroxidaseAntineutrophil cytoplasmic antibodiesHealth care costsPhysician practice patternsQuality improvementVasculitis

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.